Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance
- 24 October 2026
- journal article
- research article
- Published by Springer Nature in Diabetologia
- p. 1-14
Abstract
Aims/hypothesis Prediabetes and type 2 diabetes have been associated with more severe metabolic dysfunction-associated steatotic liver disease (MASLD), but not all individuals have the same risk and the metabolic drivers remain incompletely understood. To understand why, we examined the roles of obesity, adipose tissue dysfunction and insulin resistance in the development of significant liver fibrosis (fibrosis stage ≥F2) in adults across the glycaemic spectrum. Methods We performed a prospective, cross-sectional study in a real-world setting of adults attending primary care or endocrinology/diabetes clinics. Transient elastography was used to diagnose steatosis (controlled attenuation parameter ≥274 dB/m) and clinically significant liver fibrosis (vibration-controlled transient elastography liver stiffness measurement ≥8.2 kPa). When ≥F2 was suspected, MR-based imaging or liver biopsy was used to improve stratification. MASLD and significant fibrosis were compared across glycaemic and BMI categories and severity of insulin resistance (HOMA-IR; predominantly hepatic) and adipose tissue insulin resistance (assessed by adipose tissue insulin resistance [Adipo-IR]). Results Among the 1446 participants, the prevalence of MASLD increased across glycaemic categories from 39% in participants with normoglycaemia, to 55% in those with prediabetes and to 68% in type 2 diabetes. Clinically significant fibrosis also increased across groups, being 1%, 6% and 12%, respectively. In prediabetes, clinically significant fibrosis was rare in lean or overweight individuals even though most had associated cardiometabolic risk factors, but this increased fourfold in individuals with obesity, particularly when associated with severe adipose tissue and systemic insulin resistance. Having obesity and type 2 diabetes had the highest prevalence of clinically significant fibrosis (16%), and again, mostly if associated with insulin resistance. Most participants with clinically significant fibrosis were in the highest quintiles of Adipo-IR or HOMA-IR (Q4–Q5). Conclusions/interpretation In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin resistance. Prediabetes was a risk factor for significant fibrosis mainly in individuals with obesity and significant insulin resistance. In the context of current guidelines, MASLD risk-stratification may be improved in primary care by establishing the metabolic impact of obesity/diabetes (i.e. assessing insulin resistance by HOMA-IR). Graphical AbstractKeywords
Funding Information
- National Institutes of Health (DK-120331)
This publication has 66 references indexed in Scilit:
- Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screenObesity, 2024
- Clusters of adipose tissue dysfunction in adults with type 2 diabetes identify those with worse lipidomic profile despite similar glycaemic controlDiabetes/Metabolism Research and Reviews, 2024
- Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?Hepatology, 2022
- Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studiesDiabetologia, 2021
- Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver diseaseHepatology, 2016
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography studyHepatology, 2016
- Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitisHepatology, 2013
- Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up studyHepatology, 2012
- Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver diseaseHepatology, 2011
- Importance of Changes in Adipose Tissue Insulin Resistance to Histological Response During Thiazolidinedione Treatment of Patients with Nonalcoholic Steatohepatitis†Hepatology, 2009